BRPI0922736A8 - Sal de citrato de 11-(2-pirrolidin-1-il-etóxi)-14,19-dioxa-5,7,26-triaza-tetraciclo [19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno - Google Patents

Sal de citrato de 11-(2-pirrolidin-1-il-etóxi)-14,19-dioxa-5,7,26-triaza-tetraciclo [19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno

Info

Publication number
BRPI0922736A8
BRPI0922736A8 BRPI0922736A BRPI0922736A BRPI0922736A8 BR PI0922736 A8 BRPI0922736 A8 BR PI0922736A8 BR PI0922736 A BRPI0922736 A BR PI0922736A BR PI0922736 A BRPI0922736 A BR PI0922736A BR PI0922736 A8 BRPI0922736 A8 BR PI0922736A8
Authority
BR
Brazil
Prior art keywords
citrate salt
decaene
heptacosa
triaza
dioxa
Prior art date
Application number
BRPI0922736A
Other languages
English (en)
Inventor
Deodaunia William Anthony
Brian Dymock
Hsia Angeline Lee Cheng
Original Assignee
Cell Therapeutics Inc
Cti Biopharma Corp
Sstarbio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc, Cti Biopharma Corp, Sstarbio Pte Ltd filed Critical Cell Therapeutics Inc
Publication of BRPI0922736A2 publication Critical patent/BRPI0922736A2/pt
Publication of BRPI0922736A8 publication Critical patent/BRPI0922736A8/pt
Publication of BRPI0922736B1 publication Critical patent/BRPI0922736B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/02—Preparation of lactams
    • C07D201/10—Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

SAL DE CITRATO DE 11-(2-PIRROLIDIN-1-IL-ETÓXI)-14,19-DIOXA-5,7,26-TRIAZA-TETRACICLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENO A presente invenção refere-se a certos sais de um 11-(2-pirrolidin-1-il-etóxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno (Composto I) nos quais descobriu-se a presença de propriedades melhoradas. Em particular a presente invenção refere-se ao sal de citrato deste composto. A invenção também se refere a composições farmacêuticas contendo o sal de citrato e métodos de uso do sal citrato no tratamento de certas condições médicas. Composto I
BRPI0922736-9A 2008-12-11 2009-12-09 Sal de citrato de 11-(2-pirrolidin-1-il-etóxi)-14,19-dioxa5,7,26-triaza-tetraciclo [19.3.1.1(2,6).1 (8,12)]heptacosa1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno, composição farmacêutica compreendendo este e uso deste BRPI0922736B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12166808P 2008-12-11 2008-12-11
US61/121.668 2008-12-11
PCT/SG2009/000473 WO2010068181A1 (en) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt

Publications (3)

Publication Number Publication Date
BRPI0922736A2 BRPI0922736A2 (pt) 2017-10-31
BRPI0922736A8 true BRPI0922736A8 (pt) 2021-11-09
BRPI0922736B1 BRPI0922736B1 (pt) 2022-02-22

Family

ID=41666397

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922736-9A BRPI0922736B1 (pt) 2008-12-11 2009-12-09 Sal de citrato de 11-(2-pirrolidin-1-il-etóxi)-14,19-dioxa5,7,26-triaza-tetraciclo [19.3.1.1(2,6).1 (8,12)]heptacosa1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno, composição farmacêutica compreendendo este e uso deste

Country Status (24)

Country Link
US (2) US8980873B2 (pt)
EP (1) EP2376499B1 (pt)
JP (1) JP5669748B2 (pt)
KR (1) KR101729918B1 (pt)
CN (1) CN102282148B (pt)
AR (2) AR074724A1 (pt)
AU (1) AU2009325147B2 (pt)
BR (1) BRPI0922736B1 (pt)
CA (1) CA2746058C (pt)
DK (1) DK2376499T3 (pt)
ES (1) ES2536558T3 (pt)
HK (1) HK1161877A1 (pt)
HR (1) HRP20150428T1 (pt)
IL (3) IL213418A0 (pt)
MX (1) MX2011006206A (pt)
MY (1) MY160005A (pt)
NZ (1) NZ593223A (pt)
PL (1) PL2376499T3 (pt)
PT (1) PT2376499E (pt)
RU (1) RU2527970C2 (pt)
SG (1) SG171907A1 (pt)
TW (1) TWI449705B (pt)
WO (1) WO2010068181A1 (pt)
ZA (1) ZA201104032B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068182A1 (en) * 2008-12-11 2010-06-17 S*Bio Pte Ltd 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene maleate salt
MY160005A (en) 2008-12-11 2017-02-15 Cti Biopharma Corp 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
JP5925381B2 (ja) 2012-04-13 2016-05-25 ▲連雲▼港金康和信▲薬業▼有限公司Ｌｉａｎｙｕｎｇａｎｇ Ｊｉｎｋａｎｇ Ｈｅｘｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 化合物［４−（２−アミノ−１０−メチル−４−オキソ−６，７，８，９−テトラヒドロ−４ａ，７−エピミノピリミド［４，５−ｂ］［１，４］ジアゼピン−５（４Ｈ）−イル）ベンゾイル］−グルタメート及びその製造
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
CN1509288A (zh) * 2001-05-14 2004-06-30 �Ʒ� 5,8,14－三氮杂四环[10.3.1.02，11.04，9]－十六－2(11),3,5,7,9－五烯的柠檬酸盐
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
RU2004116311A (ru) * 2001-11-29 2005-03-27 Пфайзер Продактс Инк. (Us) Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции
WO2007058628A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Heteroalkyl linked pyrimidine derivatives
MY160005A (en) 2008-12-11 2017-02-15 Cti Biopharma Corp 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt

Also Published As

Publication number Publication date
HK1161877A1 (en) 2012-08-10
KR20110106344A (ko) 2011-09-28
TWI449705B (zh) 2014-08-21
RU2527970C2 (ru) 2014-09-10
CN102282148B (zh) 2014-12-24
WO2010068181A1 (en) 2010-06-17
SG171907A1 (en) 2011-07-28
RU2011126173A (ru) 2013-01-20
AU2009325147B2 (en) 2014-08-14
BRPI0922736B1 (pt) 2022-02-22
AR074724A1 (es) 2011-02-09
JP5669748B2 (ja) 2015-02-12
JP2012511571A (ja) 2012-05-24
WO2010068181A8 (en) 2011-08-18
EP2376499A1 (en) 2011-10-19
MX2011006206A (es) 2011-07-20
IL289379A (en) 2022-02-01
US20110294831A1 (en) 2011-12-01
CN102282148A (zh) 2011-12-14
CA2746058A1 (en) 2010-06-17
ZA201104032B (en) 2012-08-29
PL2376499T3 (pl) 2015-07-31
US9624242B2 (en) 2017-04-18
CA2746058C (en) 2016-05-17
HRP20150428T1 (en) 2015-06-19
MY160005A (en) 2017-02-15
DK2376499T3 (en) 2015-05-04
AR114133A2 (es) 2020-07-22
ES2536558T3 (es) 2015-05-26
IL250310A0 (en) 2017-03-30
TW201028426A (en) 2010-08-01
US20150322084A1 (en) 2015-11-12
NZ593223A (en) 2013-08-30
PT2376499E (pt) 2015-06-03
US8980873B2 (en) 2015-03-17
KR101729918B1 (ko) 2017-04-25
EP2376499B1 (en) 2015-02-25
BRPI0922736A2 (pt) 2017-10-31
IL213418A0 (en) 2011-07-31
AU2009325147A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
SG178952A1 (en) Chemical compounds
PH12015501678A1 (en) Inhibitors of influenza viruses replication
TR201904041T4 (tr) Protein agregasyonu ile bağlantılı hastalıklarda ve/veya nörodejeneratif hastalıklarda rol oynayan proteinlerin agregasyonunu inhibe etmeye yönelik ilaçlar.
UY32062A (es) Inhibidores de beta-secretasa
BR112012022125A2 (pt) composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
EP2415749A4 (en) NEW SALVIANOLIC ACID CONNECTION L, PREPARATION METHOD AND USE
TW200716654A (en) Sulfoximine-macrocycle compounds and salts thereof, pharmaceutical compositions comprising said compounds, methods of preparing same and uses of same
MX2011012122A (es) Derivados de tiofeno.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
BRPI0906444A8 (pt) compostos de 4-piridinona e seu uso para câncer
CL2011001178A1 (es) Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.
MX367131B (es) Sales de xantilio 3,6-disustituidas.
RU2011153353A (ru) Кетолидные соединения, обладающие противомикробной активностью
BRPI0922736A8 (pt) Sal de citrato de 11-(2-pirrolidin-1-il-etóxi)-14,19-dioxa-5,7,26-triaza-tetraciclo [19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno
MX2009006325A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
WO2011016049A3 (en) A stable composition of ready-to-use gemcitabine injection
BR112012000750A8 (pt) Sal citrato cristalino, composição farmacêutica compreendendo o referido sal e uso do mesmo
BRPI1008356A2 (pt) "sal de adição ácido de udenafil, respectivo método de preparação e composição farmacêutica"
EA201100754A1 (ru) [4-(1-аминоэтил)циклогексил]метиламины в качестве антибактериальных средств
AR074725A1 (es) Sal de maleato de 11-(2-pirrolidin-1-il-etoxi)-14,19- dioxa-5,7,26-triaza-tetraciclo(19.3.1.1 (2,6).1 (8,12) heptacosa-1(25),2 (26),3,5,8,10,12 (27),16,21,23-decaeno

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CELL THERAPEUTICS, INC. (US)

B25D Requested change of name of applicant approved

Owner name: CTI BIOPHARMA CORP. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/12/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.